JAMA Clinical Reviews
Chronic Kidney Disease and Diabetes
Dec 26, 2024
Ian H. de Boer, a nephrology expert from the University of Washington, discusses the critical link between chronic kidney disease (CKD) and diabetes. He reveals that 30-40% of diabetic patients develop CKD and emphasizes innovative prevention strategies, including lifestyle changes and screening tests like eGFR. The conversation also covers groundbreaking treatments such as SGLT2 inhibitors and finerenone, showcasing their potential to significantly reduce CKD progression and enhance patient outcomes. Don't miss these vital insights!
18:03
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Chronic kidney disease affects 30% to 40% of diabetes patients, highlighting the importance of annual monitoring for eGFR and albuminuria.
- Management strategies for CKD in diabetes now include innovative pharmacologic options like SGLT2 inhibitors and GLP-1 receptor agonists.
Deep dives
Understanding Chronic Kidney Disease (CKD) and Diabetes
Chronic kidney disease (CKD) is a prevalent condition among individuals with diabetes, marked primarily by reduced estimated glomerular filtration rate (eGFR) and elevated albuminuria. It is estimated that about one-third of diabetes patients experience CKD, and persistent abnormalities in eGFR or albuminuria are vital criteria for diagnosis. The discussion highlights the significance of consistent monitoring and screening for CKD, recommending that patients undergo annual assessments of eGFR and albuminuria, especially after a diabetes diagnosis. Understanding the epidemiology of CKD enables healthcare providers to identify those at risk and implement appropriate management strategies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
